Continuous manufacturing (CM) has emerged as a compelling alternative to traditional batch processing within the pharmaceutical industry. Two themes drive Amgen’s approach to the development and implementation of CM across the synthetic portfolio: 1) ‘flow chemistry’ as an enabling technology required to overcome the physical inefficiencies of large-scale batch manufacture (e.g., mixing, heat-transfer, light penetration, etc.), and 2) integrated end-to-end processing to deliver a significantly reduced manufacturing footprint through a next-gen hybrid design. Presented herein are case studies where the implementation of continuous manufacturing significantly improved, or simply made possible, the production-scale synthesis of chemical matter across Amgen’s synthetic portfolio.

Role of continuous manufacturing to advance Amgen’s synthetic portfolio

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.